The Role of Glucagon Like Peptide-1 in Glucose Metabolism and Weight Loss Following Gastric Bypass Surgery

Who is this study for? Patients after Bariatric Surgery
What treatments are being studied? Exendin-(9-39)
Status: Recruiting
Location: See all (2) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Early Phase 1
SUMMARY

The overall goal of this project is to understand the mechanisms by which gastric bypass surgery improves glucose metabolism. The central hypothesis guiding this project is that the reconfiguration of intestinal transit with the Roux-en-Y will increase the release of insulinotropic GI hormones, termed incretins that improve insulin secretion and glucose metabolism. The study is divided into three specific aims. 1. To determine the role of incretin hormones on insulin secretion in patients with gastric bypass surgery using intravenous-oral hyperglycemic clamp. 2. To compare incretin effect and glucose tolerance among patient who suffer from hypoglycemia after RYGB and asymptomatic surgical and non-surgical individuals. 3. To quantify the contribution of GLP-1 to incretin effect enhancement following surgery.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: t
View:

• age 18-65

• healthy control without diabetes or active organ disease

• Individuals with bariatric surgery

• recurrent hypoglycemia post gastric bypass

Locations
United States
Texas
South Texas Veterans Health Care System
RECRUITING
San Antonio
Texas Diabetes Institute - University Health System
RECRUITING
San Antonio
Contact Information
Primary
Marzieh Salehi, MD MS
salehi@uthscsa.edu
210-567-6691
Backup
Jennifer Foster, MSN
fosterj6@uthscsa.edu
210-450-8696
Time Frame
Start Date: 2005-11
Estimated Completion Date: 2027-08
Participants
Target number of participants: 80
Treatments
Experimental: hyperglycemic clamp-Meal tolerance test
these studies are to evaluate the effect of exendin-9 on insulin secretion before and after meal ingestion in patients after bariatric surgeries compared to non-surgical controls
Experimental: Labeled meal tolerance test
The effect of GLP-1 receptor blockade on glucose tolerance and glucose kinetics are evaluated in the group patients with bariatric surgery vs. nonsurgical using exendin-9-39 infusion during one of the the 2-day dual tracer studies of meal tolerance test
Related Therapeutic Areas
Sponsors
Leads: The University of Texas Health Science Center at San Antonio

This content was sourced from clinicaltrials.gov

Similar Clinical Trials